Targeting CD38 in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

EP. 1: Factors To Be Considered When Treating RRMM

December 24th 2019

EP. 2: Importance of Molecular Characterization When Treating RRMM

December 24th 2019

EP. 3: OPTIMISMM Trial: Pomalidomide in RRMM

December 24th 2019

EP. 4: Rationale for using CD38-Targeted Antibody in RRMM

December 24th 2019

EP. 5: MOA and Safety Profile of Isatuximab from the ICARIA Study

December 24th 2019

EP. 6: Sequencing of Antibodies to Treat Daratumumab Resistance

December 24th 2019

EP. 7: Emerging Therapies to Treat RRMM

December 24th 2019

Advertisement

Advertisement